Antirheumatic agents and leukocyte recruitment: New light on the mechanism of action of oxaceprol

Biochemical Pharmacology

Volumn 58, Issue 2, 1999, Pages 209-215

  Parnham, Michael J ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adhesion molecules; Antirheumatic drugs; Arthritis; Leukocyte infiltration; Oxaceprol

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; FENOPROFEN; IBUPROFEN; INDOMETACIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXACEPROL; PROSTAGLANDIN E2; SALICYLIC ACID; TENIDAP;

ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HAMSTER; HUMAN; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; CELL ADHESION; CLINICAL TRIALS; HUMANS; HYDROXYPROLINE; JOINT DISEASES; LEUKOCYTES;

EID: 0033566315     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00056-8     Document Type: Review

References (61)

1. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 39:1996;713-722.
2. Day R.O., Graham G.G., Williams K.M., Champion G.D., De Jager J. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacol Ther. 33:1987;383-433.
3. Fries J., Williams C.A., Morfeld D., Singh G., Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 39:1996;616-622.
4. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 333:1995;142-146.
5. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., Moskowitz R.W., Schnitzer T.J. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum. 38:1995;1535-1540.
6. Ionac M., Parnham M.J., Plauchithiu M., Brune K. Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res. 33:1996;367-373.
7. Harris A.G., Schropp A., Messmer K. Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. Eur J Med Res. 3:1998;182-188.
8. Flower R.J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 26:1974;33-67.
9. Vane J.R. Antiinflammatory drugs and the many mediators of inflammation. Int J Tissue React. 9:1987;1-14.
10. Vane J.R. Towards a better aspirin. Nature. 367:1994;215-216.
11. Lichtenstein D.R., Syngal S., Wolfe M.M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum. 38:1995;5-18.
12. Pairet M., Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. Vane J., Botting J., Botting R. Improved Non-Steroid Anti-Inflammatory Drugs. COX-2 Enzyme Inhibitors. 1996;103-120 Kluwer Academic Publishers, Dordrecht.
13. Williams T.J., Peck M.J. Role of prostaglandin-mediated vasodilation in inflammation. Nature. 270:1977;530-532.
14. Edwards S.W., Hallett M.B. Seeing the wood for the trees the forgotten role of neutrophils in rheumatoid arthritis . Immunol Today. 18:1997;320-324.
15. Issekutz A. Effect of vasoactive agents on polymorphonuclear leukocyte emigration in vivo. Lab Invest. 45:1981;234-240.
16. Issekutz A., Movat H.Z. The effect of vasodilator prostaglandins on polymorphonuclear leukocyte infiltration and vascular injury. Am J Pathol. 107:1982;300-309.
17. Higgs G.A., Eakins K.E., Mugridge K.G., Moncada S., Vane J.R. The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol. 66:1980;81-86.
18. Abramson S.B., Weissmann G. The mechanism of action of non-steroidal antiinflammatory drugs. Arthritis Rheum. 32:1989;1-9.
19. Díaz-González F., Sanchez-Madrid F. Inhibition of leukocyte adhesion An alternative mechanism of action for anti-inflammatory drugs . Immunol Today. 19:1998;169-172.
20. Smith M.J.H., Dawkins P.D. Salicylate and enzymes. J Pharm Pharmacol. 23:1971;729-744.
21. Frantz B., O'Neill E.A. The effect of sodium salicylate and aspirin on NF-κB. Science. 270:1995;2017-2018.
22. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
23. Madhok R. Tenidap. Lancet. 346:1995;481-485.
24. Kyan-Aung U., Lee T.H., Haskard D.O. The inhibitory effect of tenidap on leukocyte-endothelial adhesion. J Rheumatol. 20:1993;1014-1019.
25. Tang H., Neuberger J. Review article Methotrexate in gastroenterology - dangerous villain or simply misunderstood? Aliment Pharmacol Ther. 10:1996;851-858.
26. Nakajima A., Hakoda M., Yamanaka H., Kamatani N., Kashiwazaki S. Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann Rheum Dis. 55:1996;237-242.
27. Cronstein B.N. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 39:1996;1951-1960.
28. Cronstein B.N., Eberle M.A., Gruber H.E., Levine R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA. 88:1991;2441-2445.
29. Cronstein B.N., Naime D., Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 92:1993;2675-2682.
30. Pugh M.C., Pugh C.B. Current concepts in clinical therapeutics Disease-modifying drugs for rheumatoid arthritis . Clin Pharm. 6:1987;475-491.
31. Barnes P.J., Adcock I. Anti-inflammatory actions of steroids Molecular mechanisms . Trends Pharmacol Sci. 14:1993;436-441.
32. Scheineman R.J., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-290.
33. Perretti M., Flower R.J. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J Immunol. 150:1993;992-999.
34. Getting S.J., Flower R.J., Perretti M. Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Br J Pharmacol. 120:1997;1075-1082.
35. Forsyth K.D., Talbot V. Role of glucocorticoids in neutrophil and endothelial adhesion molecule expression and function. Mediat Inflamm. 1:1992;101-106.
36. Mancuso F., Flower R.J., Perretti M. Leukocyte transmigration, but not rolling or adhesion, is selectively inhibited by dexamethasone in the hamster post-capillary venule. Involvement of endogenous lipocortin 1. J Immunol. 155:1995;377-386.
37. Boschelli D.H. Inhibitors of leukocyte-endothelial cell adhesion A new generation of antiinflammatory therapeutics? Drugs Future. 20:1995;805-816.
38. Schubotz R., Hausmann L. Behandlung degenerativer Gelenkerkrankungen mit N-Azetylhydroxyprolin. Therapiewoche. 27:1977;4248-4252.
39. Soliano A. Traitement par la N-acétyl-hydroxyproline en pathologie ostéo-articulaire. Gaz Med Fr. 89:1982;1651-1654.
40. Vagt C.W., Kaiser T., Leineweber G. Wirksamkeitsvergleich der oralen Therapie mit Oxaceprol versus Ibuprofen bei Gonarthrose und Coxarthrose. Rheuma. 10:1990;263-267.
41. Hildebrandt H.-D. Therapie von Gon- und Coxarthrosen. Klinischer Vergleich von Oxaceprol und Ibuprofen. Z Allg Med. 71:1995;1742-1748.
42. Steinbach K., Bauer H.W. Klinischer Vergleich von Oxaceprol und Diclofenac bei Gon- und Koxarthrosen. Extracta Orthop. 18:1995;18-21.
43. Bauer H.W., Klasser M., von Hanstein K.L., Rolinger H., Schladitz G., Henke H.D., Gimbel W., Steinbach K. Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Clin Rheumatol. 18:1999;4-9.
44. Biehl G., Bayer I., Schäferhoff P. Therapie von Spondylarthrosen Klinischer Vergleich von Oxaceprol mit Ibuprofen . Extracta Orthop. 16:1993;18-22.
45. Richter R., King O. Vergleich der Wirksamkeit oraler Gaben von Oxaceprol und Ibuprofen in der Behandlung von Spondylarthrosen. Jatros Rheumatol. 2:1993;3-7.
46. Altman R.D., Gray R. Inflammation in osteoarthritis. Clin Rheum Dis. 11:1985;353-365.
47. Sack K.E. Osteoarthritis. A continuing challenge. West J Med. 163:1995;579-586.
48. Panayi G.S., Lanchbury J.S., Kingsley G.H. The importance of the T cell in initiating and maintaining the classic synovitis of rheumatoid arthritis. Arthritis Rheum. 35:1992;729-735.
49. Menge M. Therapie der chronischen Polyarthritis. Vergleichstudie Oxaceprol versus Diclofenac. Therapiewoche. 46:1996;1666-1669.
50. Franz M. Die Behandlung degenerativer Gelenkerkrankungen mit Oxaceprol. Rheuma. 12:1992;137-141.
51. Heite HJ and Tillessen K, Das Pyrexal-Erythem, ein "Entzündungsmodell" zur quantitativen Wirksamkeitsbestimmung entzündungshemmender Pharmaka an der menschlichen Haut. Hautarzt (Suppl 1): 160-162, 1976.
52. Mukherjee A., Hale V.G., Borga O., Stein R. Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflamm Res. 45:1996;531-540.
53. Vane J.R., Botting R.M. The mode of action of anti-inflammatory drugs. Postgrad Med J. 66:(Suppl 4):1990;S2-S17.
54. Brooks P.M., Day R.O. Nonsteroidal antiinflammatory drugs, differences and similarities. N Engl J Med. 324:1991;1716-1725.
55. Wedmore C.V., Williams T.J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 289:1981;646-650.
56. Dallegri F., Ottonello L. Tissue injury in neutrophilic inflammation. Inflamm Res. 46:1997;382-391.
57. Weichman B.M. Rat adjuvant arthritis A model of chronic inflammation . Lewis A.J., Chang J. Pharmacological Methods in the Control of Inflammation. 1989;363-380 Alan R. Liss, New York.
58. Riera H., Barbara A., Aprile F., Maheu E., Mitrovic D. Effect de l'oxacéprol sur la synthèse et la dégradation in vitro des protéoglycannes et des protéines par des explants de cartilage articulaire de veau. Rev Rhum Mal Osteoartic. 57:1990;579-583.
59. Mazières B., Maheu E., Thiéchart M., Vallières G. Effects of N-acetylhydroxyproline (Oxaceprol) on an experimental post-contusive model of osteoarthritis. A pathological study. J Drug Dev. 3:1990;135-142.
60. Dingle J.T. The effect of NSAIDs on human articular cartilage glycosaminoglycan synthesis. Eur J Rheum Inflamm. 10:1996;47-52.
61. Cronstein B.N., Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum. 36:1993;147-157.